secwatch.observer — SEC 8-K summary
======================================

Issuer:     CytomX Therapeutics, Inc. (CTMX)
CIK:        0001501989
Form:       8-K
Filed at:   2023-11-07T23:59:59+00:00
Accession:  0000950170-23-060221
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CytomX Q3 revenue $26.4M, cash $194.1M; pipeline milestones on track
--------------------------------------------------------------------

- Revenue $26.4M vs $11.1M YoY; cash $194.1M (includes ~$30M from BVF financing, $16.8M Q3 burn).
- R&D expense $16.4M (-46% YoY); G&A $6.8M (-35% YoY); no net income or EPS disclosed.
- CX-904 Phase 1a dose escalation data expected H1 2024; backfilling cohorts initiated Q4 2023.
- CX-2051 IND filing by end of 2023; Phase 1 in solid tumors in 2024 with mCRC priority.
- BMS-986288 Phase 2 ongoing; proof-of-concept data in MSS CRC and NSCLC expected in 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1501989/000095017023060221/0000950170-23-060221-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1501989/000095017023060221/ctmx-20231107.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-060221

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer